이 애플리케이션의 일부 콘텐츠는 현재 사용할 수 없습니다.
이 상황이 계속되면 다음 주소로 문의하십시오피드백 및 연락
1. (WO2019063829) IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER



면책사항 PATENTSCOPE에서 이용 가능한 이미지 버전(PDF)이 공식 버전이며, 이 온라인 HTML 버전은 사용자들에게 편의를 제공하기 위한 것입니다. 인쇄된 문서/이미지에 나타나는 정보가 정밀하고 정확하게 표현되도록 편집에 각별한 주의를 기울였음에도 불구하고, 정보의 전송, 변환 및 사용된 기계 번역 과정(선택사항)에 내재하는 한계로 인해 오류나 누락이 있을 수도 있습니다. " " 기호가 표시된 하이퍼링크는 WIPO 통제 밖의 외부 자료로 연결됩니다. 상기 사항들과 관련하여 WIPO는 어떠한 책임도 지지 않습니다.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/EP2018/076539 KARBX/P66938PC
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
28 September 2018 29 September 2017
Applicant
MELIEF, Jeroen
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
This International Searching Authority found multiple inventions in this international application, as follows:
1. claims: 1-18(completely); 19(partially)
Use of a BET inhibitor for ex vivo treating tumor cells, which can then be used in a composition for cancer treatment.
2. claims: 20-22(completely); 19, 26, 27(partially)
Use of a BET inhibitor (in vivo) in cancer treatment characterised in that the cancer comprises tumor cells that exhibit no or low levels of expression and presentation of tumor-specific neo-antigens.
3. claims: 23-25(completely); 26, 27(partially)
Use of a BET inhibitor (in vivo) in cancer treatment characterised in that the cancer comprises HLA-negative tumor cells and/or PD-L1-negative tumor cells.
1.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.
As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-18(completely); 19(partially)
Remark on Protest
The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 39/00 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, WPI Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WANG HONGWEI ET AL, "JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US,Vol. 126, No. 23, 30 November 2015 (2015-11-30), page 822,
XP009504122
11-13
Y
the whole document
1-10,14-19
(2)
Y
US 2002018767 A1 (LEE SEE-WOO [KR] ET AL) 14 February 2002 (2002-02-14)
1-10,14-19
paragraphs [0014], [0037], [0041], [0058] - [0061]
(3)
A
SHIMAMURA TAKESHI ET AL, "Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 15 NOV 2013,Vol. 19, No. 22, 15 November 2013 (2013-11-15), page 6183-6192,
XP002787559
1-19
abstract
(4)
A
WO 2016090219 A1 (H LEE MOFFITT CANCER CT & RES [US]; DANA FARBER CANCER INST INC [US]) 09 June 2016 (2016-06-09)
1-19
the whole document
(5)
A
YUKI KAGOYA ET AL, "BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models", JOURNAL OF CLINICAL INVESTIGATION,Vol. 126, No. 9, 01 September 2016 (2016-09-01), page 3479-3494,
XP055485541
1-19
the whole document
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
US 2002018767 A1
14 February 2002
KR 20020010206 A
US 2002018767 A1
04 February 2002
14 February 2002
WO 2016090219 A1
09 June 2016
AU 2015358334 A1
BR 112017011780 A2
CA 2969417 A1
CN 107223057 A
EP 3226898 A1
JP 2017537166 A
KR 20170101913 A
SG 11201704089U A
US 2017360801 A1
WO 2016090219 A1
08 June 2017
26 December 2017
09 June 2016
29 September 2017
11 October 2017
14 December 2017
06 September 2017
29 June 2017
21 December 2017
09 June 2016
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
19 December 2018
Date of mailing of the international search report:
14 March 2019
Authorized officer:
Noë, Veerle
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E